Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Nov;64(11):4686–4693. doi: 10.1128/iai.64.11.4686-4693.1996

Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

G H Lowell 1, C Colleton 1, D Frost 1, R W Kaminski 1, M Hughes 1, J Hatch 1, C Hooper 1, J Estep 1, L Pitt 1, M Topper 1, R E Hunt 1, W Baker 1, W B Baze 1
PMCID: PMC174432  PMID: 8890226

Abstract

Staphylococcal enterotoxin B (SEB), a primary cause of food poisoning, is also a superantigen that can cause toxic shock after traumatic or surgical staphylococcal wound [correction of would] infections or viral influenza-associated staphylococcal superinfections or when aerosolized for use as a potential biologic warfare threat agent. Intranasal or intramuscular (i.m.) immunization with formalinized SEB toxoid formulated with meningococcal outer membrane protein proteosomes has previously been shown to be immunogenic and protective against lethal respiratory or parenteral SEB challenge in murine models of SEB intoxication. Here, it is demonstrated that immunization of nonhuman primates with the proteosome-SEB toxoid vaccine is safe, immunogenic, and protective against lethal aerosol challenge with 15 50% lethal doses of SEB. Monkeys (10 per group) were primed i.m. and given booster injections by either the i.m. or intratracheal route without adverse side effects. Anamnestic anti-SEB serum immunoglobulin G (IgG) responses were elicited in all monkeys, but strong IgA responses in sera and bronchial secretions were elicited both pre- and post-SEB challenge only in monkeys given booster injections intratracheally. The proteosome-SEB toxoid vaccine was efficacious by both routes in protecting 100% of monkeys against severe symptomatology and death from aerosolized-SEB intoxication. These data confirm the safety, immunogenicity, and efficacy in monkeys of parenteral and respiratory vaccination with the proteosome-SEB toxoid, thereby supporting clinical trials of this vaccine in humans. The safety and enhancement of both bronchial and systemic IgA and IgG responses by the proteosome vaccine delivered by a respiratory route are also encouraging for the development of mucosally delivered proteosome vaccines to protect against SEB and other toxic or infectious respiratory pathogens.

Full Text

The Full Text of this article is available as a PDF (228.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboud-Pirak E., Lubin I., Pirak M. E., Canaan A., Lowell G. H., Reisner Y. Lethally irradiated normal strains of mice radioprotected with SCID bone marrow develop sensitivity to low doses of staphylococcal enterotoxin B. Immunol Lett. 1995 May;46(1-2):9–14. doi: 10.1016/0165-2478(94)00005-c. [DOI] [PubMed] [Google Scholar]
  2. Abraham E. Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine. 1992;10(7):461–468. doi: 10.1016/0264-410x(92)90395-z. [DOI] [PubMed] [Google Scholar]
  3. Beisel W. R. Pathophysiology of staphylococcal enterotoxin, type B, (SEB) toxemia after intravenous administration to monkeys. Toxicon. 1972 Aug;10(5):433–440. doi: 10.1016/0041-0101(72)90167-5. [DOI] [PubMed] [Google Scholar]
  4. Chen J. Y., Qiao Y., Komisar J. L., Baze W. B., Hsu I. C., Tseng J. Increased susceptibility to staphylococcal enterotoxin B intoxication in mice primed with actinomycin D. Infect Immun. 1994 Oct;62(10):4626–4631. doi: 10.1128/iai.62.10.4626-4631.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eldridge J. H., Staas J. K., Meulbroek J. A., Tice T. R., Gilley R. M. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991 Sep;59(9):2978–2986. doi: 10.1128/iai.59.9.2978-2986.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Freedman J. D., Beer D. J. Expanding perspectives on the toxic shock syndrome. Adv Intern Med. 1991;36:363–397. [PubMed] [Google Scholar]
  7. Garbe P. L., Arko R. J., Reingold A. L., Graves L. M., Hayes P. S., Hightower A. W., Chandler F. W., Broome C. V. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA. 1985 May 3;253(17):2538–2542. [PubMed] [Google Scholar]
  8. Gascoigne N. R. Interaction of the T cell receptor with bacterial superantigens. Semin Immunol. 1993 Feb;5(1):13–21. doi: 10.1006/smim.1993.1003. [DOI] [PubMed] [Google Scholar]
  9. Hajishengallis G., Hollingshead S. K., Koga T., Russell M. W. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol. 1995 May 1;154(9):4322–4332. [PubMed] [Google Scholar]
  10. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993 Sep;11(12):1179–1184. doi: 10.1016/0264-410x(93)90039-z. [DOI] [PubMed] [Google Scholar]
  11. Levi R., Aboud-Pirak E., Leclerc C., Lowell G. H., Arnon R. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine. 1995 Oct;13(14):1353–1359. doi: 10.1016/0264-410x(94)00083-y. [DOI] [PubMed] [Google Scholar]
  12. Lowell G. H., Ballou W. R., Smith L. F., Wirtz R. A., Zollinger W. D., Hockmeyer W. T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science. 1988 May 6;240(4853):800–802. doi: 10.1126/science.2452484. [DOI] [PubMed] [Google Scholar]
  13. Lowell G. H., Kaminski R. W., Grate S., Hunt R. E., Charney C., Zimmer S., Colleton C. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun. 1996 May;64(5):1706–1713. doi: 10.1128/iai.64.5.1706-1713.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lowell G. H., Smith L. F., Seid R. C., Zollinger W. D. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J Exp Med. 1988 Feb 1;167(2):658–663. doi: 10.1084/jem.167.2.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. MacDonald K. L., Osterholm M. T., Hedberg C. W., Schrock C. G., Peterson G. F., Jentzen J. M., Leonard S. A., Schlievert P. M. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA. 1987 Feb 27;257(8):1053–1058. doi: 10.1001/jama.257.8.1053. [DOI] [PubMed] [Google Scholar]
  16. Mallett C. P., Hale T. L., Kaminski R. W., Larsen T., Orr N., Cohen D., Lowell G. H. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun. 1995 Jun;63(6):2382–2386. doi: 10.1128/iai.63.6.2382-2386.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mannino R. J., Gould-Fogerite S. Lipid matrix-based vaccines for mucosal and systemic immunization. Pharm Biotechnol. 1995;6:363–387. doi: 10.1007/978-1-4615-1823-5_15. [DOI] [PubMed] [Google Scholar]
  18. Marrack P., Blackman M., Kushnir E., Kappler J. The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med. 1990 Feb 1;171(2):455–464. doi: 10.1084/jem.171.2.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990 May 11;248(4956):705–711. doi: 10.1126/science.2185544. [DOI] [PubMed] [Google Scholar]
  20. Mattix M. E., Hunt R. E., Wilhelmsen C. L., Johnson A. J., Baze W. B. Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatta). Toxicol Pathol. 1995 May-Jun;23(3):262–268. doi: 10.1177/019262339502300304. [DOI] [PubMed] [Google Scholar]
  21. McGhee J. R., Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis. 1993 Apr;2(2):55–73. [PubMed] [Google Scholar]
  22. Micusan V. V., Thibodeau J. Superantigens of microbial origin. Semin Immunol. 1993 Feb;5(1):3–11. doi: 10.1006/smim.1993.1002. [DOI] [PubMed] [Google Scholar]
  23. Miethke T., Wahl C., Heeg K., Echtenacher B., Krammer P. H., Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med. 1992 Jan 1;175(1):91–98. doi: 10.1084/jem.175.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Orr N., Robin G., Cohen D., Arnon R., Lowell G. H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun. 1993 Jun;61(6):2390–2395. doi: 10.1128/iai.61.6.2390-2395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. ROESSLER W. G., KAUTTER D. A. Modifications to the Henderson apparatus for studying air-borne infections. Evaluations using aerosols of Listeria monocytogenes. J Infect Dis. 1962 Jan-Feb;110:17–22. doi: 10.1093/infdis/110.1.17. [DOI] [PubMed] [Google Scholar]
  26. Robbins J. B., Schneerson R., Szu S. C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995 Jun;171(6):1387–1398. doi: 10.1093/infdis/171.6.1387. [DOI] [PubMed] [Google Scholar]
  27. Schantz E. J., Roessler W. G., Wagman J., Spero L., Dunnery D. A., Bergdoll M. S. Purification of staphylococcal enterotoxin B. Biochemistry. 1965 Jun;4(6):1011–1016. doi: 10.1021/bi00882a005. [DOI] [PubMed] [Google Scholar]
  28. Schlievert P. M. Role of superantigens in human disease. J Infect Dis. 1993 May;167(5):997–1002. doi: 10.1093/infdis/167.5.997. [DOI] [PubMed] [Google Scholar]
  29. Shahin R., Leef M., Eldridge J., Hudson M., Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun. 1995 Apr;63(4):1195–1200. doi: 10.1128/iai.63.4.1195-1200.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Staats H. F., Jackson R. J., Marinaro M., Takahashi I., Kiyono H., McGhee J. R. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol. 1994 Aug;6(4):572–583. doi: 10.1016/0952-7915(94)90144-9. [DOI] [PubMed] [Google Scholar]
  31. Tseng J., Komisar J. L., Trout R. N., Hunt R. E., Chen J. Y., Johnson A. J., Pitt L., Ruble D. L. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect Immun. 1995 Aug;63(8):2880–2885. doi: 10.1128/iai.63.8.2880-2885.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walker R. I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 1994 Apr;12(5):387–400. doi: 10.1016/0264-410x(94)90112-0. [DOI] [PubMed] [Google Scholar]
  33. Warren J. R., Spero L., Metzger J. F. Antigenicity of formaldehyde-inactivated staphylococcal enterotoxin B. J Immunol. 1973 Sep;111(3):885–892. [PubMed] [Google Scholar]
  34. White J., Herman A., Pullen A. M., Kubo R., Kappler J. W., Marrack P. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell. 1989 Jan 13;56(1):27–35. doi: 10.1016/0092-8674(89)90980-x. [DOI] [PubMed] [Google Scholar]
  35. Wright S. W., Trott A. T. Toxic shock syndrome: a review. Ann Emerg Med. 1988 Mar;17(3):268–273. doi: 10.1016/s0196-0644(88)80121-5. [DOI] [PubMed] [Google Scholar]
  36. el Guink N., Kris R. M., Goodman-Snitkoff G., Small P. A., Jr, Mannino R. J. Intranasal immunization with proteoliposomes protects against influenza. Vaccine. 1989 Apr;7(2):147–151. doi: 10.1016/0264-410x(89)90055-8. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES